We are live on
!
Find out more
VM
VHCP Management Portfolio holdings
AUM
$93M
1-Year Est. Return
10.04%
This Fund
S&P 500
This Quarter
Est. Return
+25.75%
1 Year Est. Return
-10.04%
3 Year Est. Return
+233.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$192M
AUM Growth
+$6.56M
(+3.5%)
Cap. Flow
-$43.6M
Cap. Flow
% of AUM
-22.67%
Top 10 Holdings %
Top 10 Hldgs %
91.02%
Holding
20
New
3
Increased
–
Reduced
8
Closed
4
Avg Time Held
2.1
quarters
Top 10 Avg Time Held
1.9
quarters
Top 20 Avg Time Held
2.1
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$5.36M |
| 2 |
Xencor
XNCR
|
+$929K |
| 3 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$578K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ironwood Pharmaceuticals
IRWD
|
+$12.1M |
| 2 |
Vanda Pharmaceuticals
VNDA
|
+$8.92M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$6.69M |
| 4 |
DYAX
DYAX CORPORATION
DYAX
|
+$5.33M |
| 5 |
CHTP
CHELSEA THERAPEUTICS INT'L LTD
CHTP
|
+$4.58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.52% |
| 2 | Miscellaneous | 34.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
GWPH
1
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $38.3M | 19.89% |
644,376
-55,000
| -8% | -$3.27M |
2013 Q2
3 quarters
|
|
|
ANAC
2
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $30.9M | 16.08% |
1,545,999
| – | – |
2013 Q2
3 quarters
|
|
3
BioCryst Pharmaceuticals
BCRX
$2.18B
| $18.5M | 9.59% |
1,744,356
-10,000
| -0.6% | -$107K |
2013 Q2
3 quarters
|
|
|
DYAX
4
DELISTED
DYAX CORPORATION
DYAX
| $18M | 9.34% |
2,000,859
-586,121
| -23% | -$5.33M |
2013 Q2
3 quarters
|
|
|
KERX
5
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $17M | 8.86% |
1,000,273
| – | – |
2013 Q2
3 quarters
|
|
6
Heron Therapeutics
HRTX
$77.1M
| $15.2M | 7.92% |
1,095,734
-1
| -0% | -$13 |
2013 Q3
2 quarters
|
|
|
7
Ironwood Pharmaceuticals
IRWD
$631M
| $11.1M | 5.76% |
1,074,600
-1,074,600
| -50% | -$12.1M |
2013 Q2
3 quarters
|
|
|
OCRX
8
DELISTED
Ocera Therapeutics, Inc.
OCRX
| $7.42M | 3.86% |
703,730
| – | – |
2013 Q4
1 quarter
|
|
|
AVDL
9
DELISTED
Avadel Pharmaceuticals
AVDL
| $6.7M | 3.48% |
+500,000
| New | +$5.36M |
2014 Q1
0 quarters
|
|
10
TherapeuticsMD
TXMD
$23.8M
| $5.34M | 2.78% |
16,930
| – | – |
2013 Q4
1 quarter
|
|
|
11
Neurocrine Biosciences
NBIX
$14.5B
| $4.89M | 2.54% |
303,503
-391,400
| -56% | -$6.69M |
2013 Q2
3 quarters
|
|
|
CHTP
12
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
| $4.35M | 2.26% |
788,370
-912,800
| -54% | -$4.58M |
2013 Q2
3 quarters
|
|
|
ALXA
13
DELISTED
Alexza Pharmaceuticals Inc
ALXA
| $1.1M | 0.57% |
247,812
-127,187
| -34% | -$652K |
2013 Q2
3 quarters
|
|
|
14
Xencor
XNCR
$1.83B
| $1.04M | 0.54% |
+88,400
| New | +$929K |
2014 Q1
0 quarters
|
|
|
ARAV
15
DELISTED
Aravive, Inc. Common Stock
ARAV
| $571K | 0.3% |
+3,167
| New | +$578K |
2014 Q1
0 quarters
|
|
|
16
Vanda Pharmaceuticals
VNDA
$276M
| – | – |
-719,075
| Closed | -$8.92M | – |
|
|
ALBO
17
DELISTED
Albireo Pharma Inc
ALBO
| – | – |
-39,883
| Closed | -$2.73M | – |
|
|
TSRO
18
DELISTED
TESARO, Inc.
TSRO
| – | – |
-137,749
| Closed | -$3.89M | – |
|
|
HPTX
19
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
| – | – |
-109,271
| Closed | -$2.21M | – |
|
Similar funds
QGI
KC
RSCM
ZC
TF
SAM
NA
NCIM
VHCP Management's Q1 2014 Portfolio in Review
As of Q1 2014, VHCP Management held 20 positions worth $192M, up 3.5% from $186M the previous quarter. Its ten largest holdings account for 91% of the portfolio.
VHCP Management withdrew a net $43.6M in Q1 2014, closing 4 positions and reducing 8 holdings. Its most notable exit was Vanda Pharmaceuticals, an estimated $8.92M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 65% a quarter earlier, followed by Miscellaneous.
Against the trend, VHCP Management opened a new position in Avadel Pharmaceuticals worth $6.7M.
- VHCP Management's largest Q1 2014 buy was Avadel Pharmaceuticals: 500,000 shares worth $6.7M.
- VHCP Management's biggest Q1 2014 reduction was Ironwood Pharmaceuticals, cutting an estimated $12.1M.
- VHCP Management fully exited Vanda Pharmaceuticals in Q1 2014, selling an estimated $8.92M.
- VHCP Management's ten largest holdings make up 91% of its $192M portfolio in Q1 2014.
- VHCP Management opened 3 new positions and closed 4 in Q1 2014.
- VHCP Management's portfolio value rose 3.5% quarter-over-quarter to $192M.
Based on VHCP Management's 13F filing for Q1 2014, filed 14 May 2014.